Targets, results, and outlook

Download (XLSX, 39 KB)
Targets, results, and outlook
Targets 20201 Results 2020 Outlook 20212
Fresenius Group
Sales growth (in constant currency) +3% to +6% 5% Low-to-mid single-digit percentage growth
Net income3 growth(in constant currency) -4% to +1% -3% At least broadly stable
Investments in property, plant and equipment ~6% to 7% of sales 7% of sales 6% of sales
Liquidity and capital management
Cash flow margin 12% to 14% 18.1% 10% to 12%
Net debt / EBITDA Around the top-end of the self-imposed target corridor of 3.0 x to 3.5 x4 3.44 x Around the top-end of the self-imposed target corridor of 3.0 x to 3.5 x4
1 Before special items; including expected COVID-19 effects (updated in July 2020; more information within table achieved Group targets in the economic report)
2 Before special items, including expected COVID-19 effects
3 Net income attributable to shareholders of Fresenius SE & Co. KGaA
4 At average expected exchange rates for both net debt and EBITDA; excluding further potential acquisitions 
   
Download (XLSX, 36 KB)
Targets, results, and outlook
Targets 20201 Results 2020 Outlook 20212
Business segments
Fresenius Medical Care
Sales growth(in constant currency) Mid-to-high single-digit %-range 5% Low-to-mid single-digit percentage growth
Net income3,4 growth (in constant currency) Mid-to-high single-digit %-range 1 2% High-teens to mid-twenties percentage decline
Fresenius Kabi
Sales growth(organic) +2% to +5% 4% Low-to-mid single-digit percentage growth
EBIT growth(in constant currency) -6% to -3% -6% Stable to low single-digit percentage growth
Fresenius Helios
Sales growth(organic) +1% to +4% 4% Low-to-mid single-digit percentage growth
EBIT growth (in constant currency) Broadly stable 0% Mid-to-high single-digit percentage growth
Fresenius Vamed
Sales growth(organic) ~ -10% -8% Mid-to-high single-digit percentage growth
EBIT Positive absolute EBIT + €29 million High double-digit € million amount
1 Before special items, including estimated COVID-19 effects (updated in October 2020, more information within table achieved Group targets in the economic report)
 2 Before special items, including estimated COVID-19 effects 
 3 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA  
4 Special items are effects that are unusual in nature and were not foreseeable or not foreseeable in size or impact at the time of giving guidance. 
Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-2294
pr-fre@fresenius.com

Visit us

Fresenius SE & Co. KGaA

Group in figures

The Group’s business model